#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Soft tissue necrosis Neuromyelitis optica spectrum disorder Hepatitis B Corneal neovascularisation Acute myeloid leukaemia recurrent Alternating hemiplegia of childhood Autoimmune disorder Neuroendocrine cell hyperplasia of infancy Factor IX deficiency Mitochondrial DNA depletion Acute myeloid leukaemia refractory Mastocytosis Diffuse large B-cell lymphoma refractory Candida infection Hypergammaglobulinaemia benign monoclonal More trials…

    Learn about Rare Diseases

    VEXAS syndrome – Basic Information Osteosarcoma metastatic – Diagnostics SAPHO syndrome – Basic Information Progressive supranuclear palsy – Life with Disease Combined immunodeficiency – Treatment Uterine leiomyosarcoma – Basic Information Splenic marginal zone lymphoma – Diagnostics Proteus syndrome – Basic Information Amyotrophic lateral sclerosis – Life with Disease Nephrotic syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Olanzapine Human Cancellous Bone Avapritinib Estriol Mepolizumab Opium, Standardized Powdered Tetracaine Hydrochloride Aztreonam Linerixibat Bi 690517 Citalopram Hydrobromide Adalimumab ZINC CHLORIDE Dutasteride Gallium (68Ga) Atomoxetine Epinephrine Hydrochloride Xaluritamig RO7837195 Botulinum Toxin Type A More therapies…

    Learn about Your Condition

    Undifferentiated sarcoma Oesophagogastroscopy Wiskott-Aldrich syndrome Neurofibromatosis External cephalic version Osteonecrosis of jaw Chronic hepatitis C Craniotomy Hypervolaemia Aphthous ulcer Alcohol use disorder Benign neoplasm of ureter B-cell lymphoma recurrent Acute kidney injury Acoustic neuroma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Uniwersytecki Szpital Kliniczny W Bialymstoku

Uniwersytecki Szpital Kliniczny W Bialymstoku

Zurawia 14, Bialystok, 15-540, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

    Recruiting

    3 1
    Investigated Diseases:
    • Glomerulonephritis membranoproliferative
    Investigated Drugs:
    • Iptacopan
    • Iptacopan Hydrochloride
    Czechia Denmark France Germany Greece Italy +4

  • Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    • Obesity
    • Overweight
    Bulgaria Czechia Denmark France Germany Greece +4

  • Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Treprostinil Palmitil
    Austria Belgium Czechia Denmark France Germany +6

  • Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Docetaxel
    • Tislelizumab
    Belgium France Germany Greece Hungary Italy +3

  • Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

    Not yet recruiting

    3 1
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study on COR-1167 for Patients with Worsening Heart Failure

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Cardiac failure
    Czechia Hungary Poland Romania Spain

  • Study on Ofatumumab Levels in Breast Milk of Women with Relapsing Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Ofatumumab
    France Germany Italy Poland

  • Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Conjunctivitis allergic
    Investigated Drugs:
    • Placebo
    Austria Germany Poland

  • Study of orforglipron in people with high blood pressure who are overweight or have obesity

    Not recruiting

    3 1
    Czechia Germany Greece Poland Spain

  • Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Systemic sclerosis pulmonary
    Investigated Drugs:
    • Tulisokibart
    Belgium France Germany Hungary Italy The Netherlands +2
Previous Page
1 … 5 6 7 8 9 … 16
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!